{"analyses":[{"ciLowerLimit":"9.5","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"42.8","estimateComment":"Stratified Mantel-Haenszel with stratification factors based on IRT.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0056","pValueComment":"Stratified by tumor location (lower limb/all other) and region (U.S./non-U.S.) based on IRT.","paramType":"Difference in responder rate","paramValue":"26.2","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37.1","upperLimit":"59.4","value":"48.2"},{"groupId":"OG001","lowerLimit":"10.8","upperLimit":"38.5","value":"22.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"83"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Participants reported responses to the BPI Worst Pain NRS. The BPI Worst Pain NRS ranged from 0 to 10, where 0 is \"no pain\" and 10 is \"pain as bad as you can imagine.\" A responder was defined as a participant who:\n\n(i) experienced a decrease of at least 30% in the mean BPI Worst Pain NRS item and (ii) did not experience a 30% or greater increase in narcotic analgesic use.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 30 mg BIW vimseltinib for 24 weeks.","id":"OG000","title":"Vimseltinib"},{"description":"Participants received matching placebo BIW for 24 weeks.","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"The ITT Set consisted of participants who were randomized to a study treatment regimen.","reportingStatus":"POSTED","timeFrame":"Baseline to Week 25 (Cycle 7, Day 1)","title":"Percentage of Participants With Response at Week 25 Based on Brief Pain Inventory (BPI) Worst Pain NRS Score and Narcotic Analgesic Use","type":"SECONDARY","unitOfMeasure":"percentage of participants"}